Contract vaccine maker IDT Biologika will bulk up its North American product pipeline when a second Canadian plant comes online, possibly as early as next summer.
The German company on Aug. 21 announced the purchase of a 32,000-square foot building in Cambridge, Ontario. The location, west of Toronto, is inside an area known as Canada’s Technology Triangle.
An IDT subsidiary, Gallant Custom Laboratories, produces autogenous veterinary biologics at another plant in Cambridge. Autogenous biologics are customized vaccines used by veterinarians when commercial vaccines are not available to treat livestock, the company noted.
“We intend to raise the bar for manufacturing technology and innovation, capacity and development of veterinary biologics in Canada,” said Andreas Kastenbauer, IDT’s managing director and head of the company’s global Animal Health Division.
“As we continue to expand our footprint across the Americas, veterinarians, farmers and government agencies in Canada and in the region are sure to reap important benefits from the breadth and depth of our capabilities that will emanate from this vaccine manufacturing hub in the years to come,” he said.